Display options
Cite
Roser AE, Caldi Gomes L, Halder R, et al. miR-182-5p and miR-183-5p Act as GDNF Mimics in Dopaminergic Midbrain Neurons. Mol Ther Nucleic Acids. 2018;11:9-22doi: 10.1016/j.omtn.2018.01.005.
Roser, A. E., Caldi Gomes, L., Halder, R., Jain, G., Maass, F., Tönges, L., Tatenhorst, L., Bähr, M., Fischer, A., & Lingor, P. (2018). miR-182-5p and miR-183-5p Act as GDNF Mimics in Dopaminergic Midbrain Neurons. Molecular therapy. Nucleic acids, 119-22. https://doi.org/10.1016/j.omtn.2018.01.005
Roser, Anna-Elisa, et al. "miR-182-5p and miR-183-5p Act as GDNF Mimics in Dopaminergic Midbrain Neurons." Molecular therapy. Nucleic acids vol. 11 (2018): 9-22. doi: https://doi.org/10.1016/j.omtn.2018.01.005
Roser AE, Caldi Gomes L, Halder R, Jain G, Maass F, Tönges L, Tatenhorst L, Bähr M, Fischer A, Lingor P. miR-182-5p and miR-183-5p Act as GDNF Mimics in Dopaminergic Midbrain Neurons. Mol Ther Nucleic Acids. 2018 Jun 01;11:9-22. doi: 10.1016/j.omtn.2018.01.005. Epub 2018 Feb 02. PMID: 29858093; PMCID: PMC5849806.
Copy Download .nbib Format: NLM
Share it on

Mol Ther Nucleic Acids. 2018 Jun 01;11:9-22. doi: 10.1016/j.omtn.2018.01.005. Epub 2018 Feb 02.

miR-182-5p and miR-183-5p Act as GDNF Mimics in Dopaminergic Midbrain Neurons.

Molecular therapy. Nucleic acids

Anna-Elisa Roser, Lucas Caldi Gomes, Rashi Halder, Gaurav Jain, Fabian Maass, Lars Tönges, Lars Tatenhorst, Mathias Bähr, André Fischer, Paul Lingor

Affiliations

  1. Department of Neurology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Lower-Saxony, Germany; DFG Cluster of Excellence Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Lower-Saxony, Germany.
  2. Department of Neurology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Lower-Saxony, Germany.
  3. Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE), Von-Siebold-Str. 3a, 37075 Göttingen, Lower-Saxony, Germany.
  4. Department of Neurology, Ruhr-Universität Bochum, Universitätsstr. 150, 44801 Bochum, NRW, Germany.
  5. DFG Cluster of Excellence Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Lower-Saxony, Germany; Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE), Von-Siebold-Str. 3a, 37075 Göttingen, Lower-Saxony, Germany; Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Von-Siebold-Str. 3a, 37075 Göttingen, Lower-Saxony, Germany.
  6. Department of Neurology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Lower-Saxony, Germany; DFG Cluster of Excellence Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Lower-Saxony, Germany. Electronic address: [email protected].

PMID: 29858093 PMCID: PMC5849806 DOI: 10.1016/j.omtn.2018.01.005

Abstract

Parkinson's disease (PD) is the second-most-frequent neurodegenerative disorder worldwide. One major hallmark of PD is the degeneration of dopaminergic (DA) neurons in the substantia nigra. Glial cell line-derived neurotrophic factor (GDNF) potently increases DA neuron survival in models of PD; however, the underlying mechanisms are incompletely understood. MicroRNAs (miRNAs) are small, non-coding RNAs that are important for post-transcriptional regulation of gene expression. Using small RNA sequencing, we show that GDNF specifically increases the expression of miR-182-5p and miR-183-5p in primary midbrain neurons (PMNs). Transfection of synthetic miR-182-5p and miR-183-5p mimics leads to increased neurite outgrowth and mediates neuroprotection of DA neurons in vitro and in vivo, mimicking GDNF effects. This is accompanied by decreased expression of FOXO3 and FOXO1 transcription factors and increased PI3K-Akt signaling. Inhibition of endogenous miR-182-5p or miR-183-5p in GDNF-treated PMNs attenuated the pro-DA effects of GDNF. These findings unveil an unknown miR-mediated mechanism of GDNF action and suggest that targeting miRNAs is a new therapeutic avenue to PD phenotypes.

Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.

Keywords: GDNF; MPTP; dopaminergic neuron; miRNA

References

  1. Brain. 2012 Nov;135(Pt 11):3355-70 - PubMed
  2. Brain Res. 2010 Jun 18;1338:3-13 - PubMed
  3. Sci Rep. 2015 Dec 21;5:18417 - PubMed
  4. Science. 2007 Aug 31;317(5842):1220-4 - PubMed
  5. Free Radic Biol Med. 2013 Sep;62:132-44 - PubMed
  6. J Neurosci. 2014 Jan 15;34(3):969-79 - PubMed
  7. Curr Opin Neurobiol. 2009 Apr;19(2):213-9 - PubMed
  8. J Cell Biol. 2003 Aug 18;162(4):613-22 - PubMed
  9. Cell. 2005 Jan 14;120(1):15-20 - PubMed
  10. Nat Commun. 2016 Aug 25;7:12594 - PubMed
  11. Neurobiol Aging. 2014 Jan;35(1):152-8 - PubMed
  12. J Neural Transm (Vienna). 1999;106(2):139-44 - PubMed
  13. Ann Neurol. 1998 Sep;44(3 Suppl 1):S121-5 - PubMed
  14. Hum Mol Genet. 2013 Aug 1;22(15):3077-92 - PubMed
  15. Neuron. 2014 Aug 6;83(3):586-600 - PubMed
  16. Nucleic Acids Res. 2014 Jan;42(Database issue):D78-85 - PubMed
  17. J Biol Chem. 2009 Aug 28;284(35):23204-16 - PubMed
  18. EMBO J. 1995 Feb 15;14(4):736-42 - PubMed
  19. Brain Res. 1998 Aug 24;803(1-2):95-104 - PubMed
  20. Mol Neurobiol. 2013 Feb;47(1):24-36 - PubMed
  21. Mol Biol Cell. 2004 Nov;15(11):4841-53 - PubMed
  22. Cancer Res. 2006 May 15;66(10):4991-5 - PubMed
  23. Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1814-9 - PubMed
  24. J Biol Chem. 2009 Apr 24;284(17 ):11285-92 - PubMed
  25. Hum Mol Genet. 2011 Aug 1;20(15):3067-78 - PubMed
  26. Cell. 2013 Jan 31;152(3):479-91 - PubMed
  27. Exp Neurol. 2008 Mar;210(1):182-93 - PubMed
  28. FEBS J. 2009 Jun;276(12 ):3269-76 - PubMed
  29. EMBO Rep. 2012 Apr;13(4):371-7 - PubMed
  30. Biochim Biophys Acta. 2000 Nov 15;1494(1-2):63-74 - PubMed
  31. J Biol Chem. 2012 Jun 8;287(24):20132-43 - PubMed
  32. Neuroscience. 2015 Aug 20;301:26-38 - PubMed
  33. Neurobiol Dis. 2015 Jan;73:150-62 - PubMed
  34. Neuropharmacology. 2000 Mar 3;39(5):777-87 - PubMed
  35. Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4281-6 - PubMed
  36. Science. 2000 Oct 27;290(5492):767-73 - PubMed
  37. Front Cell Neurosci. 2017 Apr 10;11:96 - PubMed
  38. Nature. 1995 Jan 26;373(6512):335-9 - PubMed
  39. Exp Neurol. 2013 Aug;246:72-83 - PubMed
  40. Science. 1993 May 21;260(5111):1130-2 - PubMed
  41. Oncotarget. 2014 Feb 15;5(3):740-53 - PubMed
  42. Bioinformatics. 2009 Aug 1;25(15):1991-3 - PubMed
  43. EMBO J. 2011 Sep 23;30(20):4299-308 - PubMed
  44. Nat Protoc. 2009;4(1):44-57 - PubMed
  45. Circ Res. 2012 Feb 3;110(3):496-507 - PubMed
  46. Biochem J. 2010 May 13;428(2):281-91 - PubMed
  47. FASEB J. 2006 Nov;20(13):2420-2 - PubMed
  48. J Neurochem. 2009 Nov;111(4):976-87 - PubMed
  49. Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16426-31 - PubMed
  50. Biol Open. 2014 Jan 15;3(1):81-93 - PubMed
  51. Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):E507-16 - PubMed

Publication Types